Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
Relugolix plus enzalutamide produced a sustained reduction in PSA and the combination was well tolerated. Further research including real world data should assess relugolix in doublet and triplet combinations for prostate cancer.
Authors
- Deborah Victor
- Alastair Thomson (ORCID: https://orcid.org/0000-0001-6666-1088)
- Kashyap Thakrar
- Ellis Adamson
- Lucinda Gunn
Institutions
- Royal Cornwall Hospital (GB)
- Accord (United Kingdom) (GB)
Publication Details
- Journal
- Research and Reports in Urology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/rru.s485238
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42